… strategies for patients with >1 indication for antithrombotic treatment is still unresolved. Oral
anticoagulants (OAC) are superior to antiplatelets for stroke protection in atrial fibrillation (AF) …

… Data on contraindications to oral anticoagulation therapy … of atrial fibrillation patients eligible
for oral anticoagulation treatment—… with oral anticoagulation therapy. While the proportion of …

… A retrospective observational study of nonvalvular atrial fibrillation patients initiating apixaban,
dabigatran, rivaroxaban, or warfarin from January 1, 2013, to September 30, 2015, was …

… These strokes may be effectively prevented with oral anticoagulant (OAC) therapy, using
either vitamin K antagonists (VKAs) or non-vitamin K antagonist OACs (NOACs) such as the …

… patients with AF on oral anticoagulant … patients administered oral anticoagulant treatment
(OAT) was studied by several authors (1–4). However, data remain scarce on very old patients (…

… among atrial fibrillation (AF) patients with higher C‐peak anticoagulant levels. In … oral
anticoagulants in real life patients with atrial fibrillation: results observed in four anticoagulation …

… oral anticoagulants (NOACs) with warfarin for thromboprophylaxis in patients with AF, the
efficacy and safety of NOACs in patients with mild-to-moderate CKD were similar to those in …

… patients are underrepresented in clinical trials comparing non–vitamin K antagonist oral
anticoagulants (… patients with nonvalvular atrial fibrillation (NVAF) prescribed NOACs or warfarin. …

… Direct oral anticoagulants (DOACs) are administered at fixed doses without the … anticoagulant
levels and thromboembolic events, 565 consecutive naive patients with atrial fibrillation (AF…

… Current recommendations for atrial fibrillation patients with … K antagonist in atrial fibrillation
patients 12 months after … a valid consideration for atrial fibrillation patients with stable coronary …